logo
  

Elliott Management Buys Stake In American Capital; Opposes BDC Assets Spin-off

Activist hedge fund Elliott Management Corp., which manages funds that hold an about 8.4% stake in American Capital, Ltd. (ACAS), said it has filed a presentation with the SEC urging ACAS stockholders to vote against the company's proposal to spin out BDC assets. American Capital is a private equity and venture capital firm.

Elliott said it has also created a website, www.BetterACAS.com, where ACAS stockholders and other interested parties can view the presentation and other materials regarding the Proposal's details and implications.

In conjunction with this filing, Elliott has sent a letter to the board of American Capital, proposing a five-step plan to increase stockholder value.

The plan includes withdrawing the spin-out proposal, reviewing portfolio and capital allocation, strengthening the company's board, cutting overhead costs and engaging in a meaningful strategic review to maximize shareholder value.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT